Morales, D., Beltran, B., De Mendoza, F.H., Riva, L., Yabar, A., Quinones, P., Butera, J.N. and Castillo, J. (2010) Epstein-Barr Virus as a Prognostic Factor in de Novo Nodal Diffuse Large B-Cell Lymphoma. Leukemia & Lymphoma, 51, 66-72.
http://dx.doi.org/10.3109/10428190903308015

has been cited by the following article:

• TITLE: LMP1 Immunohistochemistry in Non-Hodgkin’s Lymphoma of Sudanese Cases

  AUTHORS: Amal Ismail, Ihsan Osman, Nazik Elmalaika Husain

  KEYWORDS: Epstein Bar Virus, Latent Membrane Protein 1 LMP1, Non-Hodgkin’s Lymphoma, Immunohistochemistry

  JOURNAL NAME: Open Journal of Pathology, Vol.6 No.2, April 18, 2016

  ABSTRACT: Back ground: Non-Hodgkin’s lymphoma (NHL) with its different subtypes is strongly related to Epstein Bar virus (EBV) infection mainly Burkitt’s lymphoma in Africa. Studies proved the role of EBV in tumor-genesis and linked it to prognosis and therapy of patients. Objectives: To determine the frequency of EBV in non-Hodgkin lymphomas using EBV latent membrane protein 1 (EBV-LMP1) immunohistochemical stain. Methods: This cross-sectional study was conducted at radio-isotope centre of Khartoum (2012-2014). A total of 75 cases of non-Hodgkin lymphoma paraffin embedded sections were stained for EBV LMP1 antibody. Data were analyzed by SPSS 16 and statistical cross linking of the results of immune staining with other data was done. Results: Out of 75 patients of non Hodgkin’s lymphoma (74.7%) were males. EBV-LMP1 Immune-staining was positive in (17.3%) with predominance of Burkitt’s lymphoma (33.3%), followed by diffuse large B cell lymphoma (17.9%). Conclusion: Burkitt’s lymphoma expressed the highest percentage of non-Hodgkin’s lymphoma positive cases (46.2%) out of the total (17.3%) positive cases. Different methods need to be used in studying Burkitt’s lymphoma expression of EBV and its effects on the treatment and prognosis of cases.